Structure Therapeutics Inc. American Depositary Shares (GPCR · NASDAQ)

GPCR · MARKET VIEW

Market view · as of Jul 13, 2026

Revenue (TTM)
$0
0.0% YoY
EPS (latest q)
$-0.35
vs $-0.33 est · miss
52-wk position
47.9%
-43.1% vs 52w high · +28.5% 1mo

Price (last ~year)

Clinical-stage biopharmaceutical company Structure Therapeutics, which focuses on oral GLP-1 and amylin therapeutics, currently holds a $3.92 billion market capitalization with $0 in trailing twelve-month revenue. For the quarter ended March 31, 2026, the company reported a net loss of $76.2 million, supported by a cash position of $316.2 million against $5.8 million in total debt. Shares trade at $53.36, reflecting a 28.5% gain over the last month and an RSI of 73.

Valuation

Market cap
$3.92B
P/B
2.709
EV/EBITDA
-13.46
Beta
-1.569
Analyst target
$104.59

Quality & returns

Operating margin
0.0%
Profit margin
0.0%
ROE
-15.0%
ROA
-11.6%

Price movement

Last
$53.36
1-month
+28.5%
3-month
+0.3%
RSI (14)
73
vs SMA200
+6.0%
52-wk position
47.9% -43.1% vs high

Quarterly trajectory

Revenue by quarter (oldest → newest)

QuarterRevenueOp incomeNet incomeEBITDA
2026-03-31$0$-89.6M$-76.2M$-74.8M
2025-12-31$0$24.0M$33.0M$33.6M
2025-09-30$0$-73.8M$-65.7M$-65.3M
2025-06-30$0$-70.5M$-61.7M$-61.2M

Recent news

Sources this view read

  • fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
  • filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
  • earnings Reported earnings history (Alpha Vantage EARNINGS)
  • prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)

Other snapshots